Since the discovery that the endothelium derived relaxing factor (EDRF) was the endogenous gas nitric oxide (NO), an astonishing number of physiological functions have been attributed to NO. Despite the widely recognized importance of NO, little is known about the mechanism of regulation of the NO receptor, the soluble guanylyl cyclase (sGC). sGC is a heme-containing heterodimer that catalyzes the formation of cGMP from the substrate GTP. Upon binding of NO to the heme, the sGC is activated several hundred fold. The sGC is a multi-domain signaling enzyme that contains the receptor-heme domain, a dimerization domain and the effector-catalytic domain. It is not known how the NO signal is propagated to the catalytic domain. The proposed studies seek to understand the structural and molecular basis of mechanisms of regulation of the sGC: 1) how the NO signal is transmitted from the receptor-heme domain to the catalytic-effector domain, 2) why sGC, following prolonged exposure to NO, becomes unresponsive to NO, 3) do endogenous modulators of sGC activity play a role in this inhibition. 1) Our initial structure-based mutational analysis of the sGC heme domain and dimerization domain (solved with our collaborator Dr. van den Akker) revealed specific regions in these domains that are crucial for NO signaling. We shall investigate how these mutants affect NO activation of sGC. Guided by our structural modeling and homology with ancient conserved domains, we also seek to probe the interactions between the sGC domains that are involved in sGC allosteric activation. 2) In our quest to understand the mechanism of desensitization of sGC, we discovered that sGC is S- nitrosylated in vitro and in vivo and that S-nitrosylation correlates with the loss of responsiveness to NO- stimulation, while the basal activity remains unaltered. S-nitrosylation is a post-translational modification in which a NO moiety is added to the free-thiol of specific cysteines. We will study the mechanism of desensitization of sGC by identifying and mutating the S-nitrosylated cysteines and analyze the resulting phenotypes. 3) Recent work from our laboratory and others suggests that there are endogenous modulators for the sGC. We have discovered that protein disulfide isomerase (PDI) inhibits NO-stimulated sGC activity. We will characterize the mechanism of inhibition and address its physiological relevance. Understanding the mechanisms of regulation of sGC and identifying regulatory molecules will be key to uncovering the molecular basis of and developing compensatory therapies for some types of hypertension, atherosclerosis and erectile dysfunction, which affect more than 60 million Americans.Nitric oxide (NO) induces in the blood vessels the production of a small molecule messenger cGMP which relaxes the vasculature. Dysfunction in the NO-cGMP pathway is responsible for many cardiovascular diseases including hypertension, erectile dysfunction and atherosclerosis which affect more than 60 million Americans. We seek to understand how the production of these molecules is controlled by the body.
NIH ExPorter
NIH ExPorter